- Trials with a EudraCT protocol (103)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (2)
103 result(s) found for: Neuralgia.
Displaying page 1 of 6.
EudraCT Number: 2007-005781-12 | Sponsor Protocol Number: A6631013 | Start Date*: 2008-03-12 | |||||||||||
Sponsor Name:Pfizer Limited, Ramsgate Road, Sandwich, Kent UK | |||||||||||||
Full Title: A FOUR WEEK, MULTI-CENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP, PHASE 2A STUDY OF PH-797804 IN THE TREATMENT OF POST-HERPETIC NEURALGIA | |||||||||||||
Medical condition: Post-herpetic neuralgia (PHN) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) SE (Completed) ES (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2007-002473-31 | Sponsor Protocol Number: SCO/BIA-2093-207 | Start Date*: 2007-10-12 | |||||||||||
Sponsor Name:BIAL - Portela & Ca, S.A. | |||||||||||||
Full Title: EFFICACY AND SAFETY OF ESLICARBAZEPINE ACETATE (BIA 2 093) AS THERAPY FOR PATIENTS WITH POST-HERPETIC NEURALGIA: A DOUBLE-BLIND, DOUBLE-DUMMY, RANDOMISED, PLACEBO-CONTROLLED, PARALLEL-GROUP, MULTIC... | |||||||||||||
Medical condition: adult patients with post-herpetic neuralgia | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: PT (Completed) LT (Completed) AT (Completed) CZ (Completed) FR (Completed) HU (Completed) DE (Completed) SK (Completed) BG (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2010-023963-16 | Sponsor Protocol Number: 1014802/202 | Start Date*: 2012-01-05 | |||||||||||
Sponsor Name:Convergence Pharmaceuticals Ltd | |||||||||||||
Full Title: A Placebo-Controlled, Double-Blind Randomized Withdrawal Study to Evaluate the Safety and Efficacy of CNV1014802 in Patients with Trigeminal Neuragia | |||||||||||||
Medical condition: Trigeminal neuralgia | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) DE (Completed) DK (Completed) IT (Completed) ES (Completed) LV (Completed) LT (Completed) EE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2008-007478-39 | Sponsor Protocol Number: 42160443NPP2001 | Start Date*: 2009-10-07 | |||||||||||||||||||||
Sponsor Name:Janssen Cilag International, NV | |||||||||||||||||||||||
Full Title: A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study to Evaluate the Efficacy, Safety, and Tolerability of JNJ-42160443 in Subjects With Postherpetic Neuralgia and Post-T... | |||||||||||||||||||||||
Medical condition: Postherpetic Neuralgia and Post-Traumatic Neuralgia | |||||||||||||||||||||||
|
|||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||
Trial protocol: BE (Completed) NL (Prematurely Ended) ES (Completed) | |||||||||||||||||||||||
Trial results: View results |
EudraCT Number: 2020-004639-26 | Sponsor Protocol Number: LX9211.1-202-PHN | Start Date*: 2021-05-19 | |||||||||||
Sponsor Name:Lexicon Pharmaceuticals, Inc. | |||||||||||||
Full Title: A Phase 2, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy and Safety of LX9211 in the Treatment of Postherpetic Neuralgia (RELIEF-PHN1) | |||||||||||||
Medical condition: Postherpetic Neuralgia | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: CZ (Completed) PL (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2007-004226-25 | Sponsor Protocol Number: 07/O21 | Start Date*: 2008-03-28 | |||||||||||
Sponsor Name:UCL [...] | |||||||||||||
Full Title: Low-dose intravenous immunoglobulin or 0.9% saline in the treatment of trigeminal neuralgia refractory to carbamazepine – a randomized double blind parallel placebo-controlled multicentre trial in ... | |||||||||||||
Medical condition: Trigeminal neuralgia is a severe neuropathic facial pain that currently can often not be well controlled pharmacologically. The gold standard for medical treatment remains carbamazepine, which may ... | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2012-000399-41 | Sponsor Protocol Number: ESTEVE-SIGM-203 | Start Date*: 2012-07-23 | |||||||||||
Sponsor Name:Laboratorios del Dr. Esteve. S.A. | |||||||||||||
Full Title: An exploratory, randomized, double blind, placebo controlled, parallel groups Phase II clinical trial to evaluate the efficacy and safety of E-52862 (400 mg) by oral route, in patients with posther... | |||||||||||||
Medical condition: Postherpetic Neuralgia | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2004-002563-24 | Sponsor Protocol Number: A0081004 | Start Date*: 2005-02-25 | |||||||||||
Sponsor Name:Pfizer Ltd | |||||||||||||
Full Title: A double blind, randomised, placebo controlled trial of the time to onset of meaningful pain relief in subjects with post herpetic neuralgia (PHN) treated with pregabalin (150-600 mg /day flexible ... | |||||||||||||
Medical condition: post herpetic neuralgia | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) IT (Completed) ES (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2013-002521-27 | Sponsor Protocol Number: 8477-CL-0020 | Start Date*: 2014-05-08 | ||||||||||||||||
Sponsor Name:Astellas Pharma Europe B.V. (APEB) | ||||||||||||||||||
Full Title: A Phase 2a Enriched Enrollment Randomized Withdrawal Study to Assess Analgesic Efficacy and Safety of ASP8477 in Subjects with Peripheral Neuropathic Pain | ||||||||||||||||||
Medical condition: Peripheral Neuropathic Pain | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: DE (Completed) CZ (Completed) GB (Completed) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2008-002108-24 | Sponsor Protocol Number: SLC022/201 | Start Date*: 2009-03-10 | |||||||||||
Sponsor Name:Solace Pharmaceuticals Inc. | |||||||||||||
Full Title: A Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study Evaluating the Efficacy and Tolerability of Oral SLC022 300 mg TID, a Glial Cell Modulating Agent, Versus Placebo in the Treatme... | |||||||||||||
Medical condition: Post herpetic neuralgia | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2012-002903-16 | Sponsor Protocol Number: 2197944/201 | Start Date*: 2013-04-08 | |||||||||||
Sponsor Name:Convergence Pharmaceuticals Ltd | |||||||||||||
Full Title: A randomised, double-blind, crossover study to compare the efficacy and safety of CNV2197944 75 mg tid versus placebo in patients with post-herpetic neuralgia | |||||||||||||
Medical condition: Post-herpetic Neuralgia | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: BG (Completed) | |||||||||||||
Trial results: Removed from public view |
EudraCT Number: 2008-002208-24 | Sponsor Protocol Number: A3051103 | Start Date*: 2008-08-01 | |||||||||||
Sponsor Name:Pfizer Inc., 235 East 42nd Street,New York,NY 10017 | |||||||||||||
Full Title: A FOUR WEEK, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP, PHASE 2A STUDY OF VARENICLINE TARTRATE (CP-526,555) IN THE TREATMENT OF POST-HERPETIC NEURALGIA | |||||||||||||
Medical condition: POST-HERPETIC NEURALGIA | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: CZ (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2016-002473-35 | Sponsor Protocol Number: 802NP302 | Start Date*: 2017-05-19 | |||||||||||
Sponsor Name:Biogen Idec Research Limited | |||||||||||||
Full Title: A Phase 3 Placebo-Controlled, Double-Blind Randomized Withdrawal Study to Evaluate the Efficacy and Safety of BIIB074 in Subjects With Trigeminal Neuralgia | |||||||||||||
Medical condition: Trigeminal Neuralgia | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: CZ (Completed) HU (Prematurely Ended) ES (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2016-000280-16 | Sponsor Protocol Number: CEMA401A2201 | Start Date*: 2017-05-16 | |||||||||||
Sponsor Name:Novartis Pharma AG | |||||||||||||
Full Title: A double-blind, placebo-controlled, randomized dose ranging trial to determine the safety and efficacy of three dose levels of EMA401 in reducing 24-hour average pain intensity score in patients wi... | |||||||||||||
Medical condition: Post-herpetic neuralgia | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) GB (Prematurely Ended) SK (Prematurely Ended) AT (Prematurely Ended) NO (Prematurely Ended) DK (Prematurely Ended) ES (Prematurely Ended) CZ (Prematurely Ended) HU (Prematurely Ended) FR (Completed) BE (Prematurely Ended) PT (Prematurely Ended) PL (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2010-019101-42 | Sponsor Protocol Number: BIA-2093-308 | Start Date*: 2010-07-21 | |||||||||||
Sponsor Name:BIAL – PORTELA & Ca, S.A. | |||||||||||||
Full Title: A Phase 3, Double Blind, Randomized, Placebo Controlled, Parallel Group, Multicenter Clinical Study of Eslicarbazepine Acetate in Post-Herpetic Neuralgia | |||||||||||||
Medical condition: Post-herpetic neuralgia (PHN). | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) GB (Completed) AT (Completed) CZ (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2009-012094-35 | Sponsor Protocol Number: D5090C00018 | Start Date*: 2009-08-11 | |||||||||||
Sponsor Name:AstraZeneca AB | |||||||||||||
Full Title: A Phase IIa randomised, double-blind, placebo controlled, parallel group, multicentre study evaluating the efficacy, safety, tolerability and pharmacokinetics of AZD1386 after 3 weeks of treatment... | |||||||||||||
Medical condition: Patients with Posttraumatic Neuralgia (PTN) and Postherpetic Neuralgia (PHN) Intended Indication is Neuropathic Pain | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Prematurely Ended) FR (Completed) DK (Prematurely Ended) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2011-002083-25 | Sponsor Protocol Number: LIDO2011 | Start Date*: 2011-12-05 | ||||||||||||||||
Sponsor Name:BG University Hospital Bergmannsheil GmbH | ||||||||||||||||||
Full Title: Is there a correlation between the pain relief and the A-delta- and C-fiber function after topical application of lidocaine (5%) in patients with peripheral neuropathic pain? | ||||||||||||||||||
Medical condition: Patients with proven diagnosis of painful peripheral neuropathic pain syndromes as diagnosed as: 1. Peripheral nerve lesion or 2. Postherpetic neuralgia. | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: DE (Ongoing) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2016-001449-16 | Sponsor Protocol Number: 802NP301 | Start Date*: 2017-04-11 | |||||||||||
Sponsor Name:Biogen Idec Research Limited | |||||||||||||
Full Title: A Phase 3 Placebo-Controlled, Double-Blind Randomized Withdrawal Study to Evaluate the Efficacy and Safety of BIIB074 (Vixotrigine) in Subjects With Trigeminal Neuralgia | |||||||||||||
Medical condition: Trigeminal Neuralgia | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Ongoing) GB (GB - no longer in EU/EEA) DK (Prematurely Ended) BE (Prematurely Ended) SK (Prematurely Ended) BG (Prematurely Ended) AT (Prematurely Ended) FI (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2004-004232-31 | Sponsor Protocol Number: A6061025 | Start Date*: 2004-11-29 | |||||||||||
Sponsor Name:Pfizer Ltd | |||||||||||||
Full Title: A double-blind (third party open), placebo-controlled, parallel group, multiple dose study to investigate the safety, toleration and pharmacokinetics of [S,S]-Reboxetine in young and elderly health... | |||||||||||||
Medical condition: Postherpetic Neuralgia | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2009-016766-86 | Sponsor Protocol Number: A0081224 | Start Date*: 2011-02-21 | |||||||||||
Sponsor Name:Pfizer Inc. | |||||||||||||
Full Title: A PHASE 3 DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED, SAFETY AND EFFICACY STUDY OF ONCE DAILY CONTROLLED RELEASE PREGABALIN IN THE TREATMENT OF PATIENTS WITH POSTHERPETIC NEURALGIA (PROTOCOL A008... | |||||||||||||
Medical condition: postherpetic neuralgia | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: CZ (Prematurely Ended) SE (Completed) SK (Completed) BG (Completed) DE (Completed) HU (Completed) DK (Completed) PL (Completed) HR (Completed) | |||||||||||||
Trial results: View results |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
